HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: Strategy for targeted prolactinoma therapy

Molecular Endocrinology

Volumn 25, Issue 1, 2011, Pages 92-103

  Fukuoka, Hidenori ^a   Cooper, Odelia ^a   Mizutani, Jun ^a   Tong, Yunguang ^a   Ren, Song Guang ^a   Bannykh, Serguei ^b   Melmed, Shlomo ^a  

^a Departments of Medicine   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; GEFITINIB; LAPATINIB; MESSENGER RNA; PROLACTIN; TYKARB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN GH3; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; RAT; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR CELL LINE; TUMOR XENOGRAFT; WISTAR FURTH RAT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LACTOTROPHS; MOLECULAR TARGETED THERAPY; PROLACTIN; PROLACTINOMA; QUINAZOLINES; RATS; RECEPTOR, ERBB-2; RNA, MESSENGER; SIGNAL TRANSDUCTION;

RATTUS;

EID: 78650871897     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2010-0353     Document Type: Article

References (60)

1. Melmed S 2003 Mechanisms for pituitary tumorigenesis: The plastic pituitary. J Clin Invest 112: 1603-1618
2. Fernandez A, Karavitaki N, Wass JA 2009 Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf)
3. Ben-Jonathan N, LaPensee CR, LaPensee EW 2008 What can we learn from rodents about prolactin in humans? Endocr Rev 29: 1-41
4. Gillam MP, Molitch ME, Lombardi G, Colao A 2006 Advances in the treatment of prolactinomas. Endocr Rev 27: 485-534
5. Klibanski A 2010 Clinical practice. Prolactinomas. N Engl J Med 362: 1219-1226
6. Olafsdottir A, Schlechte J 2006 Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2: 552-561
7. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A 2006 Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65: 265-273
8. Vlotides G, Siegel E, Donangelo I, Gutman S, Ren SG, Melmed S 2008 Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res 68: 6377-6386
9. Vlotides G, Cooper O, Chen YH, Ren SG, Greenman Y, Melmed S 2009 Heregulin regulates prolactinoma gene expression. Cancer Res 69: 4209-4216
10. Murdoch GH, Potter E, Nicolaisen AK, Evans RM, Rosenfeld MG 1982 Epidermal growth factor rapidly stimulates prolactin gene transcription. Nature 300: 192-194
11. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712
12. Yarden Y, Sliwkowski MX 2001 Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137
13. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI 2007 ErbB receptors: From oncogenes to targeted cancer therapies. J Clin Invest 117: 2051-2058
14. McGuireWL1987 Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 10: 5-9
15. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA 1987 Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1: 423-430
16. Hirsch FR, Varella-Garcia M, Cappuzzo F 2009 Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28 (Suppl 1): S32-S37
17. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P 1988 Singlestep induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105-115
18. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ 1992 Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578-10582
19. Ezzat S, Zheng L, Smyth HS, Asa SL 1997 The c-erbB-2/neu protooncogene in human pituitary tumours. Clin Endocrinol (Oxf) 46: 599-606
20. Roncaroli F, Nosé V, Scheithauer BW, Kovacs K, Horvath E, Young Jr WF, Lloyd RV, Bishop MC, Hsi B, Fletcher JA 2003 Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases. J Neurosurg 99: 402-408
21. Nose-Alberti V, Mesquita MI, Martin LC, Kayath MJ 1998 Adrenocorticotropin- producing pituitary carcinoma with expression of c-erbB-2 and high PCNA index: A comparative study with pituitary adenomas and normal pituitary tissues. Endocr Pathol 9: 53-62
22. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM 2001 The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Therap 1: 85-94
23. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957
24. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S 1999 Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5: 1317-1321
25. Wang Q, Greene MI 2008 Mechanisms of resistance to ErbB-targeted cancer therapeutics. J Clin Invest 118: 2389-2392
26. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, et al. 2009 Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967
27. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn Jr PA, Hirsch FR 2005 Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive nonsmall- cell lung cancer patients. J Clin Oncol 23: 5007-5018
28. Jaffrain-Rea ML, Petrangeli E, Lubrano C, Minniti G, Di Stefano D, Sciarra F, Frati L, Tamburrano G, Cantore G, Gulino A 1998 Epidermal growth factor binding sites in human pituitary macroadenomas. J Endocrinol 158: 425-433
29. Kontogeorgos G, Stefaneanu L, Kovacs K, Cheng Z 1996 Localization of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFr) in human pituitary adenomas and nontumorous pituitaries: An immunocytochemical study. Endocr Pathol 7: 63-70
30. LeRiche VK, Asa SL, Ezzat S 1996 Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab 81: 656-662
31. Theodoropoulou M, Arzberger T, Gruebler Y, Jaffrain-Rea ML, Schlegel J, Schaaf L, Petrangeli E, Losa M, Stalla GK, Pagotto U 2004 Expression of epidermal growth factor receptor in neoplastic pituitary cells: Evidence for a role in corticotropinoma cells. J Endocrinol 183: 385-394
32. Onguru O, Scheithauer BW, Kovacs K, Vidal S, Jin L, Zhang S, Ruebel KH, Lloyd RV 2004 Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol 17: 772-780
33. Chaidarun SS, Eggo MC, Sheppard MC, Stewart PM 1994 Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology 135: 2012-2021
34. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y 1996 A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287
35. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y 1996 Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467 (Pubitemid 26151185)
36. Ben-Jonathan N, Chen S, Dunckley JA, LaPensee C, Kansra S 2009 Estrogen receptor-β mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs. Endocrinology 150: 795-802
37. Chen S, Bangaru ML, Sneade L, Dunckley JA, Ben-Jonathan N, Kansra S 2009 Epidermal growth factor receptor cross-talks with ligand-occupied estrogen receptor-β to modulate both lactotroph proliferation and prolactin gene expression. Am J Physiol Endocrinol Metab 297: E331-E339
38. Johnson LK, Vlodavsky I, Baxter JD, Gospodarowicz D 1980 Nuclear accumulation of epidermal growth factor in cultured rat pituitary cells. Nature 287: 340-343
39. Schonbrunn A, Krasnoff M, Westendorf JM, Tashjian Jr AH 1980 Epidermal growth factor and thyrotropin-releasing hormone act similarly on a clonal pituitary cell strain. Modulation of hormone production and inhbition of cell proliferation. J Cell Biol 85: 786-797
40. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins III JJ, Gilbertson R, Germain GS, Harwood FC, Houghton PJ 2004 Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64: 7491-7499
41. Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, Stewart CF 2006 Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 66: 4802-4807
42. Nahta R, Yuan LX, Du Y, Esteva FJ 2007 Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin- like growth factor I signaling. Mol Cancer Ther 6: 667-674
43. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS 2008 Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100: 1092-1103
44. Chu I, Blackwell K, Chen S, Slingerland J 2005 The dual ErbB1/ ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65: 18-25
45. Ueda S, Basaki Y, Yoshie M, Ogawa K, Sakisaka S, Kuwano M, OnoM2006 PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res 66: 5346-5353
46. Fabian MA, Biggs III WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, et al. 2005 A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336
47. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG 2000 Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892
48. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC 2005 Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 65: 338-348
49. Marti U, Ruchti C, Kämpf J, Thomas GA, Williams ED, Peter HJ, Gerber H, Bürgi U 2001 Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid 11: 137-145
50. Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL, Huo LF, Miller S, Hung MC 2009 Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 48: 610-617
51. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY, Hung MC 2005 Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7: 575-589
52. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC 2001 Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802-808
53. Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC, McIntush EW, Li LY, Hawke DH, Kobayashi R, Hung MC 2006 Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol 8: 1359-1368
54. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL 2009 Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28: 3801-3813
55. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY 2009 Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 4: E5933
56. Schlechte JA 2003 Clinical practice. Prolactinoma. N Engl J Med 349: 2035-2041
57. Goffin V, Bernichtein S, Touraine P, Kelly PA 2005 Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 26: 400-422
58. Passos VQ, Fortes MA, Giannella-Neto D, Bronstein MD 2009 Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89: 163-170
59. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE 2007 Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38: 185-189
60. McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ 2009 Low O6-methylguanine- DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71: 226-233